| Title |
Therapeutic options in peripheral T cell lymphoma
|
|---|---|
| Published in |
Journal of Hematology & Oncology, April 2016
|
| DOI | 10.1186/s13045-016-0267-0 |
| Pubmed ID | |
| Authors |
Yaping Zhang, Wei Xu, Hong Liu, Jianyong Li |
| Abstract |
Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. The standard first-line treatments have resulted in unsatisfactory patient outcomes. With the exception of low-risk anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL), the majority of patients relapse rapidly; the current 5-year overall survival rates are only 10-30 %. Novel targeted therapies and combination chemotherapies are required for the treatment of patients with PTCL. In recent years, some retrospective and prospective studies have been performed concerning PTCL. Consequently, a number of novel agents and their relevant combination therapies have been identified, including histone deacetylase inhibitors, immunoconjugates, antifolates, monoclonal antibodies, immunomodulatory agents, nucleoside analogs, proteasome inhibitors, kinase inhibitors, bendamustine, L-asparaginase, and other targeted agents. It is hoped that these innovative approaches will finally improve outcomes in patients with PTCL. This review summarizes the currently available approaches for the treatment of PTCL with an emphasis on potential new agents, including the role of stem cell transplantation. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Venezuela, Bolivarian Republic of | 2 | 33% |
| Korea, Democratic People's Republic of | 1 | 17% |
| Unknown | 3 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 83% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 44 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 20% |
| Other | 6 | 13% |
| Student > Doctoral Student | 5 | 11% |
| Professor > Associate Professor | 5 | 11% |
| Student > Master | 5 | 11% |
| Other | 8 | 17% |
| Unknown | 8 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 37% |
| Agricultural and Biological Sciences | 6 | 13% |
| Biochemistry, Genetics and Molecular Biology | 5 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Chemistry | 2 | 4% |
| Other | 3 | 7% |
| Unknown | 11 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2019.
All research outputs
#2,323,490
of 22,869,263 outputs
Outputs from Journal of Hematology & Oncology
#158
of 1,192 outputs
Outputs of similar age
#39,879
of 300,910 outputs
Outputs of similar age from Journal of Hematology & Oncology
#2
of 30 outputs
Altmetric has tracked 22,869,263 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,192 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 300,910 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.